Benefit of primary saturational biopsy in detection of localized prostatic cancer after radical prostatectomy


Cite item

Full Text

Abstract

We studied diagnostic potential of saturational technique of prostatic biopsy in 1018 males with suspected prostatic cancer (PC). Primary transrectal multifocal prostatic biopsy under ultrasound control was made in all the examinees including 453 procedures with use of saturational technique. The age of the patients varied from 43 to 77 years (median 60 years). A total of 159 patients with diagnosed prostatic cancer have undergone retropubic radical prostatectomy. Saturational biopsy has detected prostatic cancer in 35.1% cases. This technique was employed in hard for PC diagnosis parameters: age median 60 years, PSA 11.9 ng/ml, PSA density 0.23 ng/ml/cm3, prostatic volume 59.7 cm3. The above variant of biopsy detects the highest proportion of localized PC stages, minimal incidence of positive surgical margin, perineural and perivascular invasions, minimal score by Glison/s scale. Thus, the saturational technique of biopsy can be the method of choice in patients under 65 years of age, in a PSA level under 10 ng/ml, PSA density under 0.25 ng/ml/sm3 and prostatic volume over 60 cm3.

References

  1. Eichler K., Hempel S., Wilby J. et al. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J. Urol. (Baltimore) 2006; 175(5): 1605- 1612.
  2. El-Hakim A., Moussa S. CUA guidelines on prostate biopsy methodology. Can. Urol. Assoc. J. 2010; 4(2): 89-94.
  3. Говоров А. В., Пушкарь Д. Ю., Коско Д. и др. Опыт выполнения повторной сатурационной трансректальной биопсии предстательной железы. В кн.: Материалы I конгресса Российского об-ва онкоурологов. М.; 2006.
  4. Delongchamps N. B., Haas G. P. Saturation biopsies for prostate cancer: current uses and future prospects. Nature Rev. Urol. 2009; 6(12): 645-652.
  5. Taneja S. S., Mason M. Candidate selection for prostate cancer focal therapy. J. Endourol. 2010; 24(5): 1-8.
  6. Scattoni V., Raber M., Abdollah F. et al. Biopsy schemes with the fewest cores for detecting 95% of the prostate cancer detected by a 24-core biopsy. Eur. Urol. 2010; 57(1): 1-8.
  7. Huland H., Murphy G., Denis L. et al. Treatment of localized disease: treatment of clinically localized prostate cancer (T1/ T2). In: Proceedings of the First International consultation on prostate cancer. Jersey, Channel Islands: Scientific Communication International Ltd.; 1997. 227-257.
  8. Пушкарь Д. Ю., Говоров А. В., Берников А. Н. Расширенная методика трансректальной биопсии предстательной железы. Урология 2004; 2: 31-33.
  9. Prestigiacomo A. F., Stamey T. A. Physiological variation of serum prostate specific antigen in the 4.0 to 10,0 ng./ml. range in male volunteers. J. Urol. (Baltimore) 1996; 155(6): 1977-1980.
  10. Catalona W. J., Partin A. W., Slawin K. M. et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. J. A. M. A. 1998; 279(19): 1542-1547.
  11. Аничков Н. М., Плотникова Н. А. О морфологии и классификации опухолеподобных поражений и рака предстательной железы. Арх. пат. 2001; 63(6): 44-50.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies